Wave Life Sciences Ltd
For the period ended Jun 30, 2024. Filed Aug 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 8, 2024
WVE$3.48+3.4%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Consolidated Balance Sheets
| June 30, 2024 | December 31, 2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $153,958 | $200,351 |
| Accounts receivable | 1,290 | 21,086 |
| Prepaid expenses | 12,147 | 9,912 |
| Other current assets | 4,680 | 4,024 |
| Total current assets | 172,075 | 235,373 |
| Long-term assets: | ||
| Property and equipment, net of accumulated depreciation of $44,459 and $42,709 as of June 30, 2024 and December 31, 2023, respectively | 11,783 | 13,084 |
| Operating lease right-of-use assets | 20,329 | 22,637 |
| Restricted cash | 3,731 | 3,699 |
| Other assets | 900 | 156 |
| Total long-term assets | 36,743 | 39,576 |
| Total assets | $208,818 | $274,949 |
| Liabilities, Series A preferred shares, and shareholders’ equity (deficit) | ||
| Current liabilities: | ||
| Accounts payable | $18,149 | $12,839 |
| Accrued expenses and other current liabilities | 10,677 | 16,828 |
| Current portion of deferred revenue | 137,138 | 150,059 |
| Current portion of operating lease liability | 7,164 | 6,714 |
| Total current liabilities | 173,128 | 186,440 |
| Long-term liabilities: | ||
| Deferred revenue, net of current portion | 9,582 | 15,601 |
| Operating lease liability, net of current portion | 21,711 | 25,404 |
| Total long-term liabilities | 31,293 | 41,005 |
| Total liabilities | $204,421 | $227,445 |
| Series A preferred shares, no par value; 3,901,348 shares issued and outstanding at June 30, 2024 and December 31, 2023 | $7,874 | $7,874 |
| Shareholders’ equity (deficit): | ||
| Ordinary shares, no par value; 122,479,289 and 119,162,234 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively | $950,530 | $935,367 |
| Additional paid-in capital | 135,603 | 129,237 |
| Accumulated other comprehensive loss | (279) | (124) |
| Accumulated deficit | (1,089,331) | (1,024,850) |
| Total shareholders’ equity (deficit) | $(3,477) | $39,630 |
| Total liabilities, Series A preferred shares, and shareholders’ equity (deficit) | $208,818 | $274,949 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.